Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC)

被引:53
|
作者
Nakagawa, T
Otake, Y
Yanagihara, K
Miyahara, R
Ishikawa, S
Fukushima, M
Wada, H
Tanaka, F
机构
[1] Kyoto Univ, Fac Med, Dept Thorac Surg, Sakyo Ku, Kyoto 6068507, Japan
[2] Taiho Pharmaceut Co Ltd, Inst Appl Oncol, Hanno, Saitam 3578527, Japan
关键词
thymidylate synthase; non-small cell lung cancer; cell proliferation;
D O I
10.1016/j.lungcan.2003.09.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many experimental studies have revealed that enhanced thymidylate synthase (TS) expression is significantly correlated with higher proliferative activity of tumor cells, which may account for a poor prognosis of high-TS patients. However, only a few clinical studies have focused on the correlation between TS status and cell proliferation. Therefore, we assessed the correlation between TS expression and proliferative index (PI) as a marker of cell proliferation or p53 status in a total of 109 patients with completely resected pathologic stage I, non-small cell lung cancer (NSCLC). PI was defined as the percentage of tumor cells with positive staining against proliferative cell nuclear antigen (PCNA). The mean PIs of TS-high and TS-low tumors were 48.2% and 34.4% respectively, showing a significantly higher proliferative activity of TS-high tumor (P = 0.020); when stratified according to histological type, the difference was significant in adenocarcinoma (P = 0.038), but not in squamous cell carcinoma. There was no significant correlation between TS expression and p53 status. In conclusion, tumor cells with higher TS expression have higher proliferative activity in NSCLC, especially in adenocarcinoma. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:145 / 149
页数:5
相关论文
共 50 条
  • [31] Micrometastases in non-small cell lung cancer (NSCLC)
    Passlick, B
    LUNG CANCER, 2001, 34 : S25 - S29
  • [32] Immunotherapy for non-small cell lung cancer (NSCLC)
    Frost, Nikolaj
    Reck, Martin
    INNERE MEDIZIN, 2022, 63 (07): : 709 - 716
  • [33] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [34] Genotyping Non-Small Cell Lung Cancer (NSCLC)
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    GACETA MEXICANA DE ONCOLOGIA, 2012, 11 (01): : 35 - 44
  • [35] Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
    Christian Manegold
    Petr Zatloukal
    Kurt Krejcy
    Johannes Blatter
    Investigational New Drugs, 2000, 18 : 29 - 42
  • [36] BRCAness in non-small cell lung cancer (NSCLC).
    Waqar, Saiama Naheed
    Devarakonda, Siddhartha H. K.
    Michel, Loren S.
    Maggi, Leonard B.
    Watson, Mark
    Guebert, Kalin
    Carpenter, Danielle
    Sleckman, Barry P.
    Govindan, Ramaswamy
    Morgensztern, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Eicosanoids in non-small cell lung cancer (NSCLC)
    Johnson, D. H.
    Horn, L.
    Zhao, Z.
    Milne, G.
    Morrow, J.
    Sandler, A.
    Shyr, Y.
    Carbone, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Molecular marker expression in non-small cell lung cancer (NSCLC) in Humberside
    Roejkjaer, Eline
    Saleem, Azeem
    LUNG CANCER, 2024, 190
  • [39] Gemcitabine in non-small cell lung cancer (NSCLC)
    Manegold, C
    Zatloukal, P
    Krejcy, K
    Blatter, J
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 29 - 42
  • [40] Expression and localization of cyclooxygenase isoforms in non-small cell lung cancer (NSCLC)
    Watkins, DN
    Lenzo, JC
    Segal, A
    Garlepp, MJ
    Thompson, PJ
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A203 - A203